Efficacy and Safety of Pembrolizumab Plus Neoadjuvant Chemotherapy With Cisplatin and 5-Fluorouracill Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of Esophagogastric Junction
Latest Information Update: 05 Apr 2024
Price :
$35 *
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms KEYSTONE-003
- 05 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Mar 2021).
- 30 Mar 2021 New trial record